The Guardian – Business
•
03/11/2026
•
Free
Ronnie Hampel played a crucial role in reshaping ICI during the 1990s, significantly impacting the pharmaceutical sector through the creation of Zenec...
Read Full Article →
The Guardian – Business
•
03/10/2026
•
Free
The decreasing pipeline of new antibiotics poses financial risks for pharmaceutical companies due to potential increased healthcare costs and rising d...
Read Full Article →
The Guardian – Business
•
02/24/2026
•
Free
Pascal Soriot’s 6.4% pay increase to £17.7 million reflects AstraZeneca’s robust profit growth, highlighting executive compensation trends amid strate...
Read Full Article →
The Guardian – Business
•
02/10/2026
•
Free
Despite the NHS drug pricing agreement being viewed positively, AstraZeneca CEO indicates it may not generate enough financial incentive to resume the...
Read Full Article →
Globe and Mail Investing
•
02/10/2026
•
Subscription Required
AstraZeneca's forecasted growth and increased dividend reflect confidence in its expanding cancer drug portfolio and strategic investments aimed at ac...
Read Full Article →
MarketWatch Top Stories
•
02/10/2026
•
Limited Free
AstraZeneca's revenue growth and stable profit reflect strong demand for its cancer and heart medications, supporting investor confidence and potentia...
Read Full Article →
CNBC Business
•
02/02/2026
•
Free
AstraZeneca's decision to enter the New York market reflects a strategic approach to leverage the expansive U.S. financial landscape while simultaneou...
Read Full Article →
CNBC Business
•
01/28/2026
•
Free
Senior leaders from major British companies are accompanying the Prime Minister to China, underscoring efforts to strengthen economic ties despite ong...
Read Full Article →
Economic Times Markets
•
01/10/2026
•
Subscription Required
Walmart’s addition to the Nasdaq-100 highlights its growing market influence and aims to attract technology-focused investors while potentially benefi...
Read Full Article →
The Guardian – Business
•
11/06/2025
•
Free
Pascal Soriot highlighted that without increased financial commitment and revised pricing evaluations, the UK’s healthcare system may face limited acc...
Read Full Article →
The Guardian – Business
•
11/03/2025
•
Free
AstraZeneca's move to directly list shares on the New York Stock Exchange improves access for American investors and highlights opportunities to refor...
Read Full Article →
Financial Times
•
11/03/2025
•
Subscription Required
AstraZeneca’s decision to list in New York, backed by the vast majority of investors, highlights a significant shift that may impact its presence and...
Read Full Article →
City A.M.
•
10/24/2025
•
Free
If the government does not eliminate the tax on stock transactions, there could be a significant decline in both company listings in London and relate...
Read Full Article →
The Guardian – Business
•
10/10/2025
•
Free
AstraZeneca’s agreement to provide discounted medications to a U.S. government health program is expected to reduce costs for the company by preventin...
Read Full Article →
MarketWatch Top Stories
•
10/10/2025
•
Limited Free
AstraZeneca's agreement with the U.S. government aims to address medication costs, resulting in a positive market response as investors react to the c...
Read Full Article →
The Guardian – Business
•
10/01/2025
•
Free
Several major pharmaceutical companies have withdrawn billions in investments and halted collaborations, potentially impacting UK healthcare innovatio...
Read Full Article →
The Guardian – Business
•
09/29/2025
•
Free
AstraZeneca’s decision to place equal emphasis on its New York and London listings may influence investor perceptions and set a precedent that could i...
Read Full Article →
The Guardian – Business
•
09/29/2025
•
Free
AstraZeneca’s decision to list its shares directly on the New York Stock Exchange aims to enhance US investor access and valuation, potentially affect...
Read Full Article →
City A.M.
•
09/29/2025
•
Free
AstraZeneca’s decision to enhance its presence on the US market by transitioning from ADRs to a direct share listing may influence investor access and...
Read Full Article →
The Guardian – Business
•
09/29/2025
•
Free
Jaguar Land Rover’s upcoming phased manufacturing restart after a cyberattack aims to stabilize operations, while GSK’s leadership change has triggere...
Read Full Article →
The Guardian – Business
•
09/24/2025
•
Free
The opening of a new £150 million vaccine facility in Oxfordshire highlights Moderna’s ongoing commitment to the UK market despite recent tensions ove...
Read Full Article →
The Guardian – Business
•
09/16/2025
•
Free
Major pharmaceutical companies have suspended close to £2 billion in anticipated UK funding this year, impacting job security and disrupting governmen...
Read Full Article →
City A.M.
•
09/16/2025
•
Free
The withdrawal of major pharmaceutical companies from UK projects represents a significant financial blow, resulting in reduced employment opportuniti...
Read Full Article →
CNBC Business
•
07/30/2025
•
Free
AstraZeneca’s leadership suggested lowering prices on certain medications in the U.S., aiming to address market challenges and regulatory pressures af...
Read Full Article →
City A.M.
•
07/30/2025
•
Free
AstraZeneca’s potential shift toward US markets reflects broader concerns about economic incentives and growth prospects, highlighting the impact of r...
Read Full Article →
The Guardian – Business
•
07/29/2025
•
Free
AstraZeneca’s growing US market presence and substantial investment plans highlight the potential impact on its stock listing decisions and overall fi...
Read Full Article →
The Guardian – Business
•
07/29/2025
•
Free
AstraZeneca’s planned multibillion-dollar investment in the United States highlights the country’s strategic value to the company amid potential trade...
Read Full Article →
Investopedia
•
07/29/2025
•
Free
AstraZeneca's financial performance improved in the second quarter, driven by increased demand in the US market and strong sales of oncology medicatio...
Read Full Article →
Financial Times
•
07/29/2025
•
Subscription Required
AstraZeneca's revenue increased due to strong performance in the US market, coinciding with the company's announcement of a $50 billion investment to...
Read Full Article →
City A.M.
•
07/29/2025
•
Free
AstraZeneca experienced an 11 percent increase in total revenue to $28 billion in the first half, largely due to strong sales growth in its cancer tre...
Read Full Article →
